What is the appropriate second-line treatment for a 61-year-old woman with intrahepatic cholangiocarcinoma who has developed chemotherapy‑induced peripheral neuropathy after first‑line gemcitabine‑cisplatin?

Second-Line Treatment for Intrahepatic Cholangiocarcinoma with Chemotherapy-Induced Peripheral Neuropathy

For this 61-year-old woman with intrahepatic cholangiocarcinoma and chemotherapy-induced peripheral neuropathy after first-line gemcitabine-cisplatin, FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) is the recommended second-line treatment, with molecular profiling to guide targeted therapy if actionable mutations are present. 1

Treatment Algorithm

Step 1: Obtain Molecular Profiling (If Not Already Done)

The 2023 EASL-ILCA guidelines strongly recommend molecular profiling with a comprehensive panel for patients at high risk for recurrence or progression 1. This is critical because:

• FGFR2 fusions/rearrangements: If present, FGFR inhibitors (pemigatinib, infigratinib, futibatinib) should be used instead of chemotherapy 1
• IDH1 mutations: If present, ivosidenib is preferred over FOLFOX 1
• dMMR/MSI-H status: If present, immune checkpoint blockade (pembrolizumab) should be considered 1

Step 2: Choose Second-Line Chemotherapy Based on Molecular Profile

If no actionable mutations are identified:

• FOLFOX is the standard second-line chemotherapy for patients with good performance status who progressed on first-line gemcitabine-cisplatin 1

Critical consideration for this patient with peripheral neuropathy:

• FOLFOX contains oxaliplatin, which is highly neurotoxic and will worsen existing peripheral neuropathy 2
• Oxaliplatin causes both acute neuropathy (cold sensitivity, throat discomfort, muscle cramps peaking 2-3 days post-infusion) and chronic cumulative neuropathy 3
• The neuropathy from oxaliplatin exhibits a "coasting phenomenon" - it worsens for 2-3 months after stopping therapy before improving 3

Step 3: Modified Treatment Approach for This Patient

Given the pre-existing peripheral neuropathy, consider these alternatives in order of preference:

1. If FGFR2 fusion/rearrangement present: Use FGFR inhibitor (no additional neurotoxicity) 1

2. If IDH1 mutation present: Use ivosidenib (no additional neurotoxicity) 1

3. If dMMR/MSI-H and no prior durvalumab: Use pembrolizumab (no neurotoxicity) 1

4. If no actionable mutations: Use modified FOLFIRI (5-fluorouracil, leucovorin, irinotecan) instead of FOLFOX

   • FOLFIRI avoids additional platinum-induced neurotoxicity
   • Real-world data shows FOLFIRI is the most commonly used second-line regimen (57% of patients) 4
   • Median survival beyond first-line with second-line chemotherapy is 7.1 months versus 2.9 months with best supportive care 4

5. Alternative: Gemcitabine plus fluoropyrimidine (capecitabine or 5-FU) if patient had good response to first-line gemcitabine 5

Management of Existing Peripheral Neuropathy

Concurrent with second-line treatment, address the existing neuropathy:

For Symptomatic Management:

• Duloxetine 60 mg daily is the only evidence-based treatment for established painful chemotherapy-induced peripheral neuropathy 3, 6, 7
• This is a strong ASCO recommendation based on Level 1 evidence 3
• Duloxetine showed statistically significant pain reduction in patients with oxaliplatin- or paclitaxel-induced neuropathy 6
• The benefit is modest but clinically meaningful 3

Additional Considerations:

• Gabapentinoids (gabapentin, pregabalin) have weak evidence but may be tried if duloxetine is ineffective or contraindicated 7, 8
• Tricyclic antidepressants (nortriptyline preferred over amitriptyline) have limited evidence 7
• Avoid acetyl-L-carnitine - ASCO specifically recommends against its use 3

Common Pitfalls to Avoid

1. Do not use standard FOLFOX in this patient - the oxaliplatin will significantly worsen her neuropathy and may force treatment discontinuation, compromising survival benefit

2. Do not skip molecular profiling - targeted therapies offer superior outcomes without neurotoxicity for patients with actionable mutations (FGFR2 fusions occur in 10-15% of intrahepatic cholangiocarcinoma)

3. Do not delay duloxetine initiation - start immediately for symptomatic neuropathy rather than waiting to see if it improves, as established neuropathy may be irreversible 2

4. Monitor for neuropathy progression - if neuropathy worsens to Grade 3-4 or causes functional impairment, consider dose reduction, treatment delay, or switching to non-neurotoxic options 3

Performance Status Consideration

If the patient's performance status is impaired due to neuropathy or disease progression, gemcitabine monotherapy or gemcitabine plus S-1 may provide comparable efficacy with fewer adverse events 1. However, given her age (61) and assuming reasonable performance status, she should be offered full second-line therapy as outlined above.